Sorrento Therapeutics, Inc.

Symbol: SRNE




Market price today

  • -0.0238

    P/E Ratio

  • 0.0009

    PEG Ratio

  • 168.36M

    MRK Cap

  • 0.00%

    DIV Yield

Sorrento Therapeutics, Inc. (SRNE) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Henry H. Ji Ph.D.
Full-time employees:799
City:San Diego
Address:4955 Directors Place

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.

General Outlook

In simple terms, Sorrento Therapeutics, Inc. has 547.88 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.446% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -6.168%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -8.540%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -1.202% return, is a testament to Sorrento Therapeutics, Inc.'s adeptness in optimizing resource deployment. Sorrento Therapeutics, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -22.240%. Furthermore, the proficiency of Sorrento Therapeutics, Inc. in capital utilization is underscored by a remarkable -2.067% return on capital employed.

Stock Prices

Sorrento Therapeutics, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.98, while its low point bottomed out at $0.92. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Sorrento Therapeutics, Inc.'s stock market.

Liquidity Ratios

Analyzing SRNE liquidity ratios reveals its financial health of the firm. The current ratio of 50.24% gauges short-term asset coverage for liabilities. The quick ratio (38.68%) assesses immediate liquidity, while the cash ratio (26.33%) indicates cash reserves.

Current Ratio50.24%
Quick Ratio38.68%
Cash Ratio26.33%

Profitability Ratios

SRNE profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -860.21% underscores its earnings before tax deductions. The effective tax rate stands at -1.68%, revealing its tax efficiency. The net income per EBT, 99.27%, and the EBT per EBIT, 139.46%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -616.81%, we grasp its operational profitability.

Pretax Profit Margin-860.21%
Effective Tax Rate-1.68%
Net Income per EBT99.27%
EBT per EBIT139.46%
EBIT per Revenue-616.81%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 0.50, it details the span from stock purchase to revenue.

Days of Sales Outstanding39
Days of Inventory Outstanding99
Operating Cycle284.72
Days of Payables Outstanding190
Cash Conversion Cycle95
Receivables Turnover1.96
Payables Turnover1.92
Inventory Turnover3.69
Fixed Asset Turnover0.60
Asset Turnover0.14

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.33, and free cash flow per share, -0.35, depict cash generation on a per-share basis. The cash per share value, 0.13, showcases liquidity position. A payout ratio of -0.03 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, -2.78, offers insight into cash flow relative to sales.

Operating Cash Flow per Share-0.33
Free Cash Flow per Share-0.35
Cash per Share0.13
Payout Ratio-0.03
Operating Cash Flow Sales Ratio-2.78
Free Cash Flow to Operating Cash Flow Ratio1.05
Cash Flow Coverage Ratio-0.86
Short Term Coverage Ratio-1.34
Capital Expenditure Coverage Ratio-21.19
Dividend Paid and Capex Coverage Ratio-7.87

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 45.46%, highlights its total liabilities relative to assets. With a debt-equity ratio of 1.87, we discern the balance between debt and equity financing. The long-term debt to capitalization, 40.07%, and total debt to capitalization, 65.17%, ratios shed light on its capital structure. An interest coverage of 502.43 indicates its ability to manage interest expenses.

Debt Ratio45.46%
Debt Equity Ratio1.87
Long Term Debt to Capitalization40.07%
Total Debt to Capitalization65.17%
Interest Coverage502.43
Cash Flow to Debt Ratio-0.86
Company Equity Multiplier4.12

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.15, provides a glimpse into top-line earnings distributed across each share. Net income per share, -1.33, reflects the portion of profit attributed to each share. The book value per share, -0.04, represents the net asset value distributed per share, while the tangible book value per share, -0.57, excludes intangible assets.

Revenue Per Share0.15
Net Income Per Share-1.33
Book Value Per Share-0.04
Tangible Book Value Per Share-0.57
Shareholders Equity Per Share-0.04
Interest Debt Per Share0.34
Capex Per Share-0.03

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 482,383,090, captures the company's total value, considering both debt and equity. Income quality, 0.51, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 45.93%, indicates the value of non-physical assets, and capex to operating cash flow, 4.65%, measures reinvestment capability.

Enterprise Value482,383,090
Income Quality0.51
Research and Development to Revenue352.05%
Intangibles to Total Assets45.93%
Capex to Operating Cash Flow4.65%
Capex to Revenue-21.73%
Capex to Depreciation-103.11%
Stock-Based Compensation to Revenue119.11%
Graham Number1.15
Return on Tangible Assets-218.77%
Graham Net Net-1.00
Working Capital-231,549,000
Tangible Asset Value-238,840,000
Net Current Asset Value-398,136,000
Invested Capital-7
Average Receivables21,592,000
Average Payables37,464,500
Average Inventory9,041,000
Days Sales Outstanding142
Days Payables Outstanding518
Days of Inventory On Hand109

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.12, and the price to book ratio, 0.12, reflect the market's valuation relative to the company's book value. The price to sales ratio, 0.20, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -0.07, and price to operating cash flows, -0.07, gauge market valuation against cash flow metrics.

Price Book Value Ratio0.12
Price to Book Ratio0.12
Price to Sales Ratio0.20
Price Cash Flow Ratio-0.07
Enterprise Value Multiple0.34
Price Fair Value0.12
Price to Operating Cash Flow Ratio-0.07
Price to Free Cash Flows Ratio-0.07
Price to Tangible Book Ratio-19.97
Enterprise Value to Sales7.68
Enterprise Value Over EBITDA-1.32
EV to Operating Cash Flow-1.64
Earnings Yield-150.55%
Free Cash Flow Yield-82.77%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Sorrento Therapeutics, Inc. (SRNE) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.024 in 2024.

What is the ticker symbol of Sorrento Therapeutics, Inc. stock?

The ticker symbol of Sorrento Therapeutics, Inc. stock is SRNE.

What is company IPO date?

IPO date of Sorrento Therapeutics, Inc. is 2007-01-19.

What is company current share price?

Current share price is 0.307 USD.

What is stock market cap today?

The market cap of stock today is 168363520.000.

What is PEG ratio in 2024?

The current 0.001 is 0.001 in 2024.

What is the number of employees in 2024?

In 2024 the company has 799.